Interventional, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Delayed-Start Study to Evaluate the Efficacy and Safety of Eptinezumab in Patients With Episodic Cluster Headache
Interventional, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Delayed-Start Study to Evaluate the Efficacy and Safety of Eptinezumab in Patients With Episodic Cluster Headache
The purpose of this study is to evaluate the efficacy of eptinezumab in participants with episodic Cluster Headache (eCH)
Eligible participants will be randomly assigned to receive treatment, in a blinded manner, two infusions of either eptinezumab or placebo in a cross-over manner during the Placebo-controlled Period and Active Treatment Period of the study.
The total duration of the study after randomization is 24 weeks, including a safety follow-up period of 8 weeks.
Inclusion Criteria:
Exclusion Criteria
Other inclusion and exclusion criteria may apply.
Denver, Colorado 80218, United States
Philadelphia, Pennsylvania 19107, United States
Clermont-Ferrand, Auvergne-Rhône-Alpes 63003, France
Essen, North Rhine-Westphalia 45133, Germany
Rome, Roma 00163, Italy
Milan, 20133, Italy
Naples, 280138, Italy
Pavia, 27100, Italy
Saitama-shi, Saitama 338-8577, Japan
Lisbon, Lisbon District 1649-035, Portugal
Nizhny Novgorod, Nizhny Novgorod Oblast 603076, Russia
Perm, Permsky 614990, Russia
Newcastle upon Tyne, England NE7 7DN, United Kingdom